Key evidence points: GLP-1 medications do not directly target or break down muscle tissue Lean mass loss occurs as a consequence of the calorie deficit and weight reduction The proportion of lean mass lost is comparable to other weight loss methods Greater absolute lean mass loss reflects the greater total weight loss achieved Regulatory bodies including NICE and the MHRA have not identified muscle loss as a specific adverse effect requiring special warnings in the Summary of Product Characteristics (SmPCs), though healthcare professionals are advised to monitor nutritional status and encourage appropriate dietary protein intake and physical activity in patients using these medications for weight management
GLP-1 medications primarily influence how much you eat, but they dont necessarily improve how your body uses and stores energy
Drug-drug interactions may occur when two or more medicines are taken together, resulting in a higher risk of side effects or decreased efficacy of one or both medications
Can patients regain weight after stopping GLP-1 medications
being the major increase in the GPx enzyme (approximately at 190 %), followed by GST enzyme (approximately at 170 %), GSH (approximately at 160 %), and finally GR enzyme (approximately at 140 %)
Most people get through their first week without major issues